MSD and Erasca collaborate on clinical trial for RAS-mutant tumours
Merck & Co (MSD) and Erasca have entered a clinical trial collaboration and supply agreement to assess ERAS-0015 in combination…
All articles by Salong Debbarma
Salong Debbarma
-
-
Inhibrx announces positive interim results from HexAgon trial
Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve,…
-
Actio Biosciences begins trial of ABS-1230 for epilepsy
Actio Biosciences has begun the KYRON Phase Ib/II trial of ABS-1230 for potassium sodium-activated channel subfamily T member 1 (KCNT1)-related…
-
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
Day One Biopharmaceuticals has concluded patient enrolment in the Phase III FIREFLY-2 trial assessing tovorafenib for paediatric low-grade glioma (pLGG).…
-
enGene reports interim data from LEGEND trial of detalimogene voraplasmid
enGene Therapeutics has reported additional interim outcomes from the pivotal cohort of its ongoing LEGEND Phase II trial assessing detalimogene…
-
MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer
MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early human epidermal growth…
-
Taimei Technology and C&R Research to develop AI clinical trial operations platform
Taimei Technology and South Korea’s C&R Research have signed a strategic partnership deal to co-develop an AI-powered clinical trial operations…
-
Patient enrolment concludes in Alebund’s Phase III trial of AP301
Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial, RESPOND-2, Study AP301-HP-03, evaluating the fibre-iron-based…
-
Oragenics opens second site for ONP-002 Phase IIa trial
Oragenics has activated a second site for its ongoing Phase IIa clinical trial of ONP-002, its lead treatment candidate for…
-
Nocion completes patient enrolment in Phase IIb ASPIRE trial
Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE study assessing taplucainium as a treatment for refractory or…